Neuromuscular blocking drugs in the critically ill
Published Date: 18th March 2021
Publication Authors: Welhengama C
The pharmacology of neuromuscular blocking drugs (NMBDs) in the critically ill was reviewed in this journal 15 yrs ago. However, the clinical indications for the use of these drugs in such patients in the intervening period has evolved considerably. This article provides an update on the current indications and evidence base for the use of NMBDs in intensive care. In particular, the changing approach to the use of NMBDs in patients with acute respiratory distress syndrome (ARDS) based on recent research is considered, as is the use of NMBDs in patients with coronavirus disease 2019 (COVID-19) and before proning. More stress on the need for neuromuscular monitoring whenever NMBDs have been given is detailed.
Welhengama, C; Hall, A; Hunter, JM. (2021). Neuromuscular blocking drugs in the critically ill. British Journal of Anaesthesia. epub 18 Mar